[go: up one dir, main page]

CO5271720A1 - Proceso para fabricar selectivamente hemipentahidrato y monopentahidrato de acido 3-piridil-12hidroxi-etiliden-1, 1-bisfofosnico sodio y composicion farmacetica que las contiene - Google Patents

Proceso para fabricar selectivamente hemipentahidrato y monopentahidrato de acido 3-piridil-12hidroxi-etiliden-1, 1-bisfofosnico sodio y composicion farmacetica que las contiene

Info

Publication number
CO5271720A1
CO5271720A1 CO01006628A CO01006628A CO5271720A1 CO 5271720 A1 CO5271720 A1 CO 5271720A1 CO 01006628 A CO01006628 A CO 01006628A CO 01006628 A CO01006628 A CO 01006628A CO 5271720 A1 CO5271720 A1 CO 5271720A1
Authority
CO
Colombia
Prior art keywords
sodium
acid
hemipentahydrate
pharmacetic
monopentahydrate
Prior art date
Application number
CO01006628A
Other languages
English (en)
Inventor
Frederick Dana Cazer
Gregory Eugene Perry
Dennis Michael Billings
Furey Nancy Lee Redman
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22656866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5271720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5271720A1 publication Critical patent/CO5271720A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con un proceso para fabricar selectivamente hemipentahidrato y monohidrato de ácido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfónico sodio que comprende los pasos:proveer una solución acuosa de ácido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfónico sodio;calentar solución acuosa a una temperatura de 45°C a 75°C aproximadamente;añadir un disolvente a la solución acuosa; yenfriar opcionalmente la solución acuosa.Igualmente, se refiere a una composición farmacéuticamente que las contiene.
CO01006628A 2000-02-01 2001-01-30 Proceso para fabricar selectivamente hemipentahidrato y monopentahidrato de acido 3-piridil-12hidroxi-etiliden-1, 1-bisfofosnico sodio y composicion farmacetica que las contiene CO5271720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17950500P 2000-02-01 2000-02-01

Publications (1)

Publication Number Publication Date
CO5271720A1 true CO5271720A1 (es) 2003-04-30

Family

ID=22656866

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01006628A CO5271720A1 (es) 2000-02-01 2001-01-30 Proceso para fabricar selectivamente hemipentahidrato y monopentahidrato de acido 3-piridil-12hidroxi-etiliden-1, 1-bisfofosnico sodio y composicion farmacetica que las contiene

Country Status (33)

Country Link
US (1) US6410520B2 (es)
EP (1) EP1252170B2 (es)
JP (5) JP2003521532A (es)
KR (1) KR100549038B1 (es)
CN (1) CN1183148C (es)
AR (1) AR030187A1 (es)
AT (1) ATE273984T1 (es)
AU (1) AU784307B2 (es)
BR (1) BRPI0107921B8 (es)
CA (1) CA2399976C (es)
CO (1) CO5271720A1 (es)
CZ (1) CZ303400B6 (es)
DE (1) DE60104978T3 (es)
DK (1) DK1252170T4 (es)
ES (1) ES2225481T5 (es)
HK (1) HK1051046B (es)
HU (1) HU230494B1 (es)
IL (2) IL150511A0 (es)
MA (1) MA25654A1 (es)
MX (1) MXPA02007417A (es)
MY (1) MY119968A (es)
NO (1) NO329923B1 (es)
NZ (1) NZ519966A (es)
PE (1) PE20011061A1 (es)
PL (1) PL207589B1 (es)
PT (1) PT1252170E (es)
RU (1) RU2236415C2 (es)
SA (1) SA01220066B1 (es)
SK (1) SK287884B6 (es)
TR (1) TR200402435T4 (es)
TW (1) TWI310769B (es)
WO (1) WO2001056983A2 (es)
ZA (1) ZA200205090B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011061A1 (es) * 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
CN101024654A (zh) * 2002-04-11 2007-08-29 特瓦制药工业有限公司 利塞膦酸钠的新多晶型物和假多晶型物
EP1923052A1 (en) 2002-04-11 2008-05-21 Teva Pharmaceutical Industries Ltd Novel polymorphs and pseudopolymorphs of risedronate sodium
CZ293349B6 (cs) * 2002-10-25 2004-04-14 Léčiva, A.S. Nová krystalická forma sodné soli kyseliny 3-pyridyl-1-hydroxyethyliden-1,1-bisfosfonové
CA2513543A1 (en) * 2003-01-17 2004-08-05 Teva Pharmaceutical Industries Ltd. Risedronate sodium having a very low content of iron
HUP0300227A2 (hu) * 2003-01-28 2004-09-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
WO2005012314A1 (en) * 2003-07-30 2005-02-10 The Procter & Gamble Company Process for controlling crystal structure of risedronate
CZ298639B6 (cs) * 2004-02-05 2007-12-05 Zentiva, A. S. Krystalická forma risedronátu monosodného
US7618953B2 (en) * 2004-02-26 2009-11-17 Zentiva, A.S. Amorphous forms of risedronate monosodium
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
NZ551118A (en) 2004-05-24 2010-09-30 Warner Chilcott Co Llc Enteric solid oral dosage form of bisphosphonate containing a chelating agent
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
EP1828214A4 (en) * 2004-11-09 2008-08-13 Jubilant Organosys Ltd PROCESS FOR THE SYNTHESIS OF A PURE POLYMORPHIC FORM OF SODIUM 3-PYRIDYL-1-HYDROXYETHYLIDINE-1,1-BISPHOSPHONATE
PL199215B1 (pl) * 2004-12-28 2008-08-29 Politechnika Gdanska Sposób wytwarzania kwasu [1-hydroksy-2-(3-pirydylo)etylidenobisfosfonowego] oraz jego soli monosodowej dwu i pół wodnej
ES2324015T1 (es) * 2005-05-06 2009-07-29 Medichem, S.A. Proceso de sintesis de acidos bisfosfonicos geminales o de sus sales farmaceuticamente aceptables o de sus hidratos.
US7872144B2 (en) * 2005-06-13 2011-01-18 Jubilant Organosys Limited Process for producing biphosphonic acids and forms thereof
AR054673A1 (es) * 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
GB0519891D0 (en) * 2005-09-30 2005-11-09 Pliva Hrvatska D O O Pharmaceutically acceptable salts and hydrates
EP1775302A1 (en) * 2005-10-11 2007-04-18 Sandoz A/S Method for preparing crystalline sodium risedronate
WO2007042048A2 (en) * 2005-10-11 2007-04-19 Sandoz A/S Method for preparing crystalline sodium risedronate
EP1981896B1 (en) * 2006-01-20 2013-03-13 Aurobindo Pharma Limited An improved process for the preparation of risedronate sodium hemi-pentahydrate
JP5354858B2 (ja) * 2006-05-09 2013-11-27 株式会社Ａｄｅｋａ スルホンアミド化合物の金属塩を含有するポリエステル樹脂組成物
MX2008014248A (es) 2006-05-11 2009-02-23 Ind Swift Lab Ltd Proceso para la preparacion de sales y acido risedronico puros.
CA2656053A1 (en) * 2006-07-03 2008-01-10 Generics [Uk] Limited Novel process for the preparation of bisphosphonic acids
WO2008065542A2 (en) * 2006-09-22 2008-06-05 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for the preparation of risedronate sodium
WO2008044245A2 (en) * 2006-10-10 2008-04-17 Matrix Laboratories Ltd A process for the preparation of risedronate sodium hemipentahydrate
KR100828705B1 (ko) 2006-12-04 2008-05-09 씨제이제일제당 (주) 리세드론산 나트륨 수화물의 제조방법
KR100775440B1 (ko) * 2006-12-20 2007-11-12 동우신테크 주식회사 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법
KR100798855B1 (ko) * 2007-02-14 2008-01-28 주식회사 엔지켐 리세드론산 나트륨 헤미펜타하이드레이트의 제조방법
KR100812528B1 (ko) * 2007-04-12 2008-03-12 보령제약 주식회사 리세드로네이트 나트륨염의 헤미펜타히드레이트의 선택적결정화방법
US20100317859A1 (en) * 2007-05-16 2010-12-16 Actavis Group Ptc Ehf Process for the Preparation of Risedronate Sodium
WO2009050731A2 (en) * 2007-06-20 2009-04-23 Alkem Laboratories Ltd Novel process for preparing risedronic acid
DE102007030370A1 (de) 2007-06-29 2009-01-02 Ratiopharm Gmbh Essigsäure-Solvate von Risedronat, Polymorph hiervon, deren Herstellung und Verwendung sowie pharmazeutische Zusammensetzung, enthaltend diese
KR100925835B1 (ko) * 2007-12-07 2009-11-06 동우신테크 주식회사 리세드로네이트 나트륨 무수물 및 수화물의 제조방법
KR101010062B1 (ko) 2008-04-11 2011-01-21 주식회사 대희화학 증발 결정화를 이용한 결정상 리세드로네이트 모노소듐모노하이드레이트의 제조방법
JP2013510097A (ja) * 2009-11-03 2013-03-21 リウ、リー タンシノンｉｉａスルホン酸ナトリウム水和物、並びにその調製方法及び使用
SI3319970T1 (sl) * 2015-07-08 2019-12-31 Daiichi Sankyo Company Pirido-oksazinon derivati kot TNAP inhibitorji
KR102368241B1 (ko) 2017-06-06 2022-02-28 미쯔비시 케미컬 주식회사 폴리오르가노실록산 함유 그래프트 공중합체, 열가소성 수지 조성물 및 성형체

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
US4447256A (en) 1977-07-20 1984-05-08 Nissan Chemical Industries, Ltd. N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4330537A (en) 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
JPS5598193A (en) 1979-01-22 1980-07-25 Nissan Chem Ind Ltd Methylenediphosphonic acid derivative and herbicide comprising it as active constituent
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
PH27078A (en) * 1984-12-21 1993-02-01 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonates
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
IT1187750B (it) 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
DE3773716D1 (de) 1986-03-24 1991-11-21 Nippon Kayaku Kk Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung.
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0275821B1 (de) 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren
DE3700772A1 (de) 1987-01-13 1988-07-21 Inst Khim Kinetiki I Gorenija Verfahren zur herstellung von i-funktionellsubstituierten alkyliden-i,i-diphosphonsaeuren und deren gemischen
US5091525A (en) 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US5035898A (en) 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
US5110807A (en) 1988-12-01 1992-05-05 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3917153A1 (de) 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
MX21453A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
MX21452A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
TW208013B (es) 1990-03-01 1993-06-21 Daiichi Co Ltd
ATE120753T1 (de) 1990-08-21 1995-04-15 Upjohn Co Bisphosphonsäurederivate als antiarthritische mittel.
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
IT1246992B (it) 1991-01-08 1994-12-12 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici e loro sali
DK58291D0 (da) 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
ATE195075T1 (de) * 1991-11-22 2000-08-15 Procter & Gamble Pharma Risedronat enthaltende arzneimittel mit verzögerter wirkstoffabgabe
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US5317015A (en) 1992-05-01 1994-05-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Azacyclic bisphosphonates as anticholesterolemic agents
AU4356693A (en) 1992-06-23 1994-01-24 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
FR2694558B1 (fr) 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
PL311278A1 (en) 1993-04-28 1996-02-05 Pfizer Crystalline glycosidal spirostantil monohydrate
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
TW257765B (es) * 1993-08-25 1995-09-21 Merck & Co Inc
US5580977A (en) 1995-03-01 1996-12-03 Eli Lilly And Company Process for preparing loracarbef monohydrate
TW393488B (en) 1995-04-20 2000-06-11 Merck & Co Inc Process for making 1-hydrox-ybisphosphonates
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
JP2000504718A (ja) 1996-02-14 2000-04-18 バインダーマン，イザク 骨吸収を予防するための局所用ビスホスホネート
EP0939624B1 (en) 1996-05-17 2003-12-17 Merck & Co., Inc. Effervescent bisphosphonate formulation
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
IL133405A0 (en) * 1997-06-11 2001-04-30 Procter & Gamble Film-coated tablet for improved upper gastrointestinal tract safety
DK0891979T3 (da) * 1997-07-15 2005-01-31 Gador Sa Krystallinsk form af N,N-dimethyl-3-amino-1-hydroxypropan-1,1-diphosphonsyre-mononatrium-monohydrat og fremgangsmåde til fremstilling heraf
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
JP2002518457A (ja) * 1998-06-24 2002-06-25 メルク エンド カムパニー インコーポレーテッド 骨吸収阻害用の組成物および方法
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
PE20011061A1 (es) * 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato

Also Published As

Publication number Publication date
JP2014208716A (ja) 2014-11-06
ES2225481T5 (es) 2014-02-19
MY119968A (en) 2005-08-30
JP2016028083A (ja) 2016-02-25
TR200402435T4 (tr) 2004-12-21
RU2236415C2 (ru) 2004-09-20
NO329923B1 (no) 2011-01-24
ATE273984T1 (de) 2004-09-15
DK1252170T4 (da) 2014-01-20
DE60104978T3 (de) 2014-04-03
AU3473601A (en) 2001-08-14
JP5859930B2 (ja) 2016-02-16
JP2010159264A (ja) 2010-07-22
WO2001056983A2 (en) 2001-08-09
TWI310769B (en) 2009-06-11
NO20023645D0 (no) 2002-07-31
KR20020071976A (ko) 2002-09-13
BR0107921A (pt) 2002-10-22
PL357097A1 (en) 2004-07-12
EP1252170B2 (en) 2013-11-06
IL150511A (en) 2006-12-10
MXPA02007417A (es) 2002-12-09
US20020002282A1 (en) 2002-01-03
PL207589B1 (pl) 2011-01-31
DK1252170T3 (da) 2004-12-13
ES2225481T3 (es) 2005-03-16
CA2399976A1 (en) 2001-08-09
HUP0204203A3 (en) 2005-02-28
SK287884B6 (sk) 2012-02-03
JP5900553B2 (ja) 2016-04-06
RU2002123369A (ru) 2004-01-10
MA25654A1 (fr) 2002-12-31
BRPI0107921B8 (pt) 2021-05-25
EP1252170B1 (en) 2004-08-18
AR030187A1 (es) 2003-08-13
CN1183148C (zh) 2005-01-05
ZA200205090B (en) 2003-04-30
DE60104978D1 (de) 2004-09-23
US6410520B2 (en) 2002-06-25
HUP0204203A2 (en) 2003-05-28
CZ303400B6 (cs) 2012-08-29
HU230494B1 (hu) 2016-09-28
CN1396926A (zh) 2003-02-12
PT1252170E (pt) 2004-12-31
WO2001056983A3 (en) 2002-03-07
CA2399976C (en) 2007-03-27
EP1252170A2 (en) 2002-10-30
IL150511A0 (en) 2003-02-12
BRPI0107921B1 (pt) 2020-11-10
JP2003521532A (ja) 2003-07-15
AU784307B2 (en) 2006-03-09
HK1051046A1 (en) 2003-07-18
KR100549038B1 (ko) 2006-02-02
JP5405343B2 (ja) 2014-02-05
HK1051046B (zh) 2005-04-29
NZ519966A (en) 2004-03-26
SK11002002A3 (sk) 2003-02-04
JP2012255013A (ja) 2012-12-27
SA01220066B1 (ar) 2006-11-25
PE20011061A1 (es) 2001-11-20
NO20023645L (no) 2002-10-01
DE60104978T2 (de) 2005-08-18

Similar Documents

Publication Publication Date Title
CO5271720A1 (es) Proceso para fabricar selectivamente hemipentahidrato y monopentahidrato de acido 3-piridil-12hidroxi-etiliden-1, 1-bisfofosnico sodio y composicion farmacetica que las contiene
AR082581A2 (es) Procedimientos de preparacion de combretastatinas
ES8608874A1 (es) Un procedimiento para la preparacion de una 2-(1h)-quinolona
GT200200105A (es) Nueva composicion farmaceutica
ES2079567T3 (es) Procedimiento para preparar composiciones de jabon-isetionato de acilo.
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
ES8606879A1 (es) Un procedimiento para la preparacion de derivados esteroida-les
GT200000190A (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas-4-carboxiamino-2-sustituidas.
DOP2002000512A (es) Sales de acido succinato de 5,7,14-triazatetraciclo [10.3.1.0² ¹¹.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
ECSP034917A (es) Nuevos derivados de acido sulfonico
DK2308496T3 (da) Formulering indeholdende fosfatderivater af elektrontransfermidler
AR247878A1 (es) Procedimiento para preparar antagonistas receptores fibrinogenos
MX2021011484A (es) Composiciones de d-metirosina y metodos para preparar las mismas.
BR9506727A (pt) Processo para a recemização do substrato de piperazino-2-terc-butil-carboxamida e composto
DK1289930T3 (da) Fremgangsmåde til fremstilling af 5-aminosalicylsyre
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR051341A1 (es) Proceso para la preparacion de derivados de [1,4,5]-oxadiazepina
ES2109828T3 (es) Procedimiento para la preparacion de cloruro ferrico en solucion acuosa.
ES2162351T3 (es) Metodos para la preparacion de derivados de benzofenona.
ES8703423A1 (es) Un procedimiento para producir un derivado de acido indola- cetico
BR9402148A (pt) Processo para a preparação da forma cristalina monohidratada de um composto, forma cristalina e composto
ES2079616T3 (es) Procedimiento de cristalizacion en presencia de un campo magnetico.
ES2128031T3 (es) Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina.
BRPI9916280B8 (pt) Processo de preparação de para-trifluorometilanilinas poli-halogenadas.
PE20010155A1 (es) Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas

Legal Events

Date Code Title Description
FC Application refused